New Three-Drug cocktail aims to tackle Hard-to-Treat multiple myeloma

NCT ID NCT07348393

Not yet recruiting Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial is testing a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—in 70 adults with relapsed or refractory multiple myeloma. The goal is to see if this combo can slow or stop the cancer from growing. Participants must have already tried lenalidomide and an anti-CD38 antibody but never used carfilzomib before.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mezigdomide, carfilzomib, and dexamethasone
What this could lead to: If successful, this could offer a new treatment option for multiple myeloma patients whose cancer has returned or stopped responding to other therapies.
What could go wrong: This is an early Phase 2 trial with only 70 participants, so results may not apply to all patients. The combination may cause side effects and might not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Contacts and locations

Locations

Saint-Antoine Hospital

Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.